Potent and selective allosteric Akt1, Akt2 and Akt3 inhibitor
MK 2206 dihydrochloride is a potent and selective allosteric Akt inhibitor (IC50 values are 5 nM, 12 nM, and 65 nM for Akt1, Akt2, and Akt3, respectively). MK 2206 requires the Pleckstrin homology domain for its activity, and exhibits no inhibitory activity in a panel of 250 tested protein kinases. MK 2206 induces growth inhibition of different cancer cell lines (IC50 in the range 3.4 and 28.6 μmol/L) and enhances antitumor efficacy of a range of standard chemotherapeutics. It synergistically inhibits cell proliferation of human lung and breast cancer cells in combination with Erlotinib (Cat. No. 7194) by suppressing both the Ras/Erk and PI 3-K pathways
in vitro
in vivo
. MK 2206 can be used to block the IL-22 - Akt signaling pathway for studying paneth cell differentiation.
| Marque | Tocris Bioscience |
|---|---|
| Réf. B-LABO | BL-RE-125047 |
| Réf. fabricant | 30000034 |
| Nom chimique ou matériau | 8-[4-(1-Aminocyclobutyl)phenyl]-9-phenyl-1,2,4-triazolo[3,4-f][1,6]naphthyridin-3(2H)-one dihydrochloride |
| CAS | 1032350-13-2 |
| Quantité | 10 mg |
| Cible | Akt (Protein Kinase B) Inhibitors |
| Formule moléculaire | C<sub>25</sub>H<sub>21</sub>N<sub>5</sub>O.2HCl |
| Pureté | 0.98 |
